Asthma – Epidemiology – Europe

Clarivate Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of asthma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s asthma forecast will answer the following questions:

• In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of asthma?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of asthma over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 5 asthma patient populations, as follows:

• Diagnosed 12-month prevalent cases.
• Diagnosed symptomatic 12-month prevalent cases.
• Diagnosed medically controlled 12-month prevalent cases.
• Diagnosed 12-month prevalent cases by severity.
• Diagnosed drug-treated 12-month prevalent cases.

Note: coverage may vary by country.